What Lemsip Cold & Flu Treats: Main Uses and Benefits

The primary role of this medicine is to provide supportive symptomatic relief for the acute, disruptive manifestations associated with the common cold and influenza.

The product is intended for the short-term relief of these illness symptoms, including aches and pains, nasal congestion, sore throat, and managing symptoms related to fever. It is generally applied in contexts involving heightened systemic burden and localized discomfort, and supports individuals during symptomatic episodes by easing distress.

“The multi-action approach is relevant in situations where symptoms form part of acute episodes and create temporary functional strain.”

This formulation is used where short-term symptomatic support is needed, addressing groups of symptoms that may appear suddenly and interfere with daily comfort. The medication plays a role in managing pronounced systemic manifestations, as well as localized discomforts like sinus pressure and a blocked nose.

Key Domains of Symptomatic Support
Systemic Discomfort	Helps ease generalized body aches and headache.
Elevated Temperature	Supports the management of fever (pyrexia).
Nasal Strain	Assists with relieving congestion and sinus pressure.

Eligibility Map: Who can and cannot use Lemsip Cold & Flu — official regulatory information

Official regulatory documents establish strict criteria regarding who may use Lemsip Cold & Flu, primarily based on the presence of paracetamol and decongestants like phenylephrine.

Contraindicated Populations (Must Not Use):

• Individuals with known hypersensitivity to paracetamol, phenylephrine, or any other component in the formulation.
• Patients currently taking, or who have taken Monoamine Oxidase Inhibitors (MAOIs) within the last 14 days.
• Patients using any other paracetamol-containing products or other sympathomimetic decongestants.
• Individuals with severe cardiovascular disorders, severe coronary heart disease, or hypertension (high blood pressure).
• Patients with hyperthyroidism (overactive thyroid), phaeochromocytoma, diabetes mellitus, or closed-angle glaucoma.

Age-Related Eligibility:

• The medicine is not suitable for children under 12 or 16 years of age, depending on the specific product formulation (e.g., Lemsip Max is often restricted to 16 years and over).
• Adults and the elderly are the primary eligible population.

Conditional Use (Requires Caution/Professional Advice):

• Use is restricted for patients with impaired liver or kidney function, requiring special care.
• Use is generally avoided or not recommended during pregnancy and breastfeeding unless specifically advised by a healthcare professional, due to the phenylephrine content and possible risks.
• Caution is advised for patients with a history of stomach or peptic ulcers, prostatic enlargement, or those who are malnourished or consume excess alcohol (due to paracetamol risk).

Connection to the overall eligibility profile: The regulatory profile strictly limits use to prevent adverse drug-disease interactions, especially concerning the cardiovascular system and liver safety. The medicine is formally contraindicated in multiple populations with severe underlying conditions and requires explicit avoidance during physiological states like pregnancy, thereby defining clear boundaries for safe population use.

Interactions with other medicines and products

Interaction Scope

Property	Description
Medicinal product categories with documented interactions	Monoamine Oxidase Inhibitors (MAOIs), Sympathomimetic Decongestants, Liver Enzyme-Inducing Drugs, Antihypertensives, Cardiac Glycosides, Oxytocic Agents, Anticoagulants, and specific Antibiotics (Flucloxacillin).
Timing-based interaction rules	Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is prohibited during therapy and for 14 days after stopping MAOI therapy.
Interaction-related restrictions	Must not be co-administered with any other sympathomimetic decongestants or any other product containing paracetamol.

Official Interaction Statements

The regulatory profile includes strict statements on combination use. Co-administration with MAOIs is formally contraindicated due to the documented risk of hypertensive interactions. The phenylephrine component may reduce the efficacy of Beta-blockers and other antihypertensives and increases the risk of cardiovascular side effects when combined with Tricyclic Antidepressants or Cardiac Glycosides.

Interactions with the acetaminophen component involve altered exposure and toxicity risk. Metoclopramide and Domperidone may increase the rate of absorption, while Cholestyramine may reduce it. Alcohol, Isoniazid, and other Liver Enzyme-Inducing Drugs may increase the hepatotoxic potential of paracetamol. The anticoagulant effect of Warfarin is enhanced only by prolonged regular use of paracetamol, while occasional doses have no significant effect. Caution is noted with Flucloxacillin in populations with underlying risk factors such as renal impairment or sepsis.

Modulating Central Thermoregulation and Pain Signaling

This domain involves Paracetamol acting primarily on specific enzyme isoforms (Cyclooxygenase, or COX) within the Central Nervous System. This action functionally inhibits the synthesis of Prostaglandin E2 in the hypothalamus and spinal cord, which in turn dampens the body's elevated temperature set point and alters pain signal transmission, promoting a return of the elevated thermal set point to normal and altering central pain signal transmission.

Targeted Vasoconstriction in Upper Respiratory Passages

This mechanism is driven by Phenylephrine through its direct activation (agonism) of Alpha-1 (alpha1) Adrenergic Receptors on the smooth muscle of blood vessels in the nasal and sinus mucosa. Activating these receptors initiates a cellular cascade that causes the vessels to narrow (vasoconstriction), which restricts blood flow and fluid leakage, thereby resulting in a decrease in local fluid volume and tissue edema in the upper respiratory tract.

Dual Mechanism for Broad Physiological Influence

The final physiological consequence results from the two components influencing two independent biological systems: one central (regulating temperature/pain) and one peripheral (regulating local vascular tone). This dual approach engages mechanisms associated with both CNS-mediated signaling and autonomic receptor-mediated responses, resulting in simultaneous, integrated physiological alterations across these distinct mechanistic domains.

Recommended Usage and Dosage

Lemsip Cold & Flu powder for oral solution typically contains the active ingredients paracetamol (an analgesic and antipyretic) and phenylephrine hydrochloride (a nasal decongestant) in varying strengths, such as 650 mg/10 mg or 1000 mg/12.2 mg per sachet, depending on the specific product variant.

It is designed for oral administration after dissolving in water.

Patient Group	Recommended Dosage (Powder)	Maximum Daily Dose
Adults and Children 16+	One sachet dissolved in hot water. May be repeated every 4 to 6 hours as required.	Do not exceed four sachets (four doses) in any 24-hour period.
Children under 16	Not typically recommended.	Consult a doctor or pharmacist for pediatric products.

Method of Administration:

1. Dissolve the entire content of one sachet by stirring it into a mug of hot, but not boiling, water.
2. Consume the solution while warm. Sweeteners such as sugar or honey may be added to taste.

Important Safety Information:

• Do not exceed the stated dose. Immediate medical attention must be sought in the event of an overdose, even if no symptoms are present, due to the risk of delayed, severe liver damage from paracetamol.
• Do not take this product concurrently with any other medicine containing paracetamol or other decongestants.
• If symptoms persist for more than five days, or worsen, discontinue use and consult a healthcare professional.

Recent Clinical Evidence

The relief of common cold and flu-like symptoms is supported by studies that investigate the combination of its two primary active ingredients: paracetamol (an analgesic and antipyretic) and phenylephrine hydrochloride (a nasal decongestant).

---

Efficacy in Symptom Reduction

Clinical trials, including randomized, placebo-controlled studies, have evaluated the symptomatic treatment of upper respiratory tract infections in adults. These investigations focus on how the active ingredients influence overall symptom scores, fever, and nasal congestion.

• Paracetamol's Role: Research consistently shows that paracetamol, when used alone or in combination, is associated with a reduction in fever (antipyretic effect) and relief from general aches and pains (analgesic effect) linked to colds and flu.
• Phenylephrine's Role: Phenylephrine acts as a vasoconstrictor, which is studied for its potential to relieve nasal congestion by reducing swelling in the nasal passages. Studies comparing decongestants often measure changes in nasal air flow.

Combination Therapy Findings

Fixed-dose combinations containing paracetamol and phenylephrine are studied to assess their impact on multiple symptoms simultaneously, simplifying the approach to symptom management. Some randomized trials involving combinations (which may also include other ingredients) observed a significantly greater reduction in total symptom scores in the treatment groups compared to placebo over short treatment durations (e.g., 48–72 hours).

Symptom Evaluated (Study Focus)	Research Outcome Measure
Pain and Headache	Reduction in symptom intensity scales
Fever/High Temperature	Change in core body temperature
Nasal Congestion	Subjective symptom scores and objective air flow measures

Safety and Tolerability

The safety profile of the combination is evaluated in clinical settings. Adverse events noted in clinical trials are generally consistent with the known side effects of the individual components. The most commonly reported events are non-serious and may include gastrointestinal issues or central nervous system effects such as nervousness or headache, particularly associated with the decongestant component. Long-term cardiovascular data related to oral phenylephrine are subject to ongoing review and discussion by regulatory bodies.

Key Studies & References

1. Evaluation of Efficacy and Safety of Tablets of Paracetamol, Dimethindene Maleate and Phenylephrine Hydrochloride in Reducing Symptoms of Common Cold and Flu (Trial NCT01448057)

Common questions about Lemsip Cold & Flu (FAQ)

---

Q: Can I drink alcohol while taking Lemsip Cold & Flu?

Regulatory documents and official product information indicate that this product should not be taken with large quantities of alcohol. Chronic alcoholism is noted as a disease interaction risk. Alcohol may increase the risk of delayed, serious liver damage from the paracetamol component.

---

Q: Can I take Lemsip while pregnant or breastfeeding?

Official regulatory documents indicate that this product should generally be avoided during pregnancy and lactation. This is primarily due to the phenylephrine component. Consultation with a healthcare professional is necessary before use during these periods.

---

Q: What should I do if I accidentally take more than the recommended dose?

Immediate medical attention must be sought in the event of an accidental overdose, even if you feel well and have no immediate symptoms. Overdosing on paracetamol, one of the active ingredients, carries the risk of severe, delayed liver damage.

---

Q: How long should I wait before driving after taking Lemsip?

The product is not generally classified as causing sleepiness. However, official information on undesirable effects reports side effects such as dizziness and headache. It is important to be aware of how the medicine affects you before driving or operating machinery.

---

Q: I have a sore throat, can I mix Lemsip with honey?

The product's method of administration permits the addition of sweeteners, such as sugar or honey, to the prepared solution to improve the taste. This is mentioned in the official instructions for preparing the drink.

How to Store and Dispose of Lemsip Cold & Flu?

To maintain the quality and safety of this medicine, follow the labeled storage requirements:

• Temperature: Store the product below 25 C.
• Protection: Keep the product in its original package and store the powder for oral solution in a dry place.
• Children: Always ensure the product is stored out of the sight and reach of children.
• Expiry: Do not use the medicine after the expiration date printed on the packaging.

Disposal

Proper disposal is required to protect the environment. Do not dispose of Lemsip Cold & Flu via household waste or wastewater, such as flushing it down a toilet or pouring it down a sink. Instead, ask your pharmacist for guidance on how to safely throw away medicines that are no longer needed.